WS Management’s CRISPR Therapeutics CRSP Stock Holding History

WS Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,876	Closed	-$1.18M	–	61
2023 Q4	$1.18M	Hold	18,876	–	–	0.07%	60
2023 Q3	$857K	Hold	18,876	–	–	0.07%	63
2023 Q2	$1.06M	Hold	18,876	–	–	0.09%	57
2023 Q1	$854K	Hold	18,876	–	–	0.09%	53
2022 Q4	$767K	Hold	18,876	–	–	0.07%	60
2022 Q3	$1.23M	Hold	18,876	–	–	0.11%	61
2022 Q2	$1.15M	Hold	18,876	–	–	0.09%	64
2022 Q1	$1.19M	Hold	18,876	–	–	0.06%	61
2021 Q4	$1.43M	Hold	18,876	–	–	0.11%	52
2021 Q3	$2.11M	Hold	18,876	–	–	0.22%	56
2021 Q2	$3.06M	Hold	18,876	–	–	0.3%	52
2021 Q1	$2.3M	Sell	18,876 -964	-5%	-$146K	0.24%	50
2020 Q4	$3.04M	Hold	19,840	–	–	0.32%	38
2020 Q3	$1.66M	Hold	19,840	–	–	0.18%	50
2020 Q2	$1.46M	Sell	19,840 -3,412	-15%	-$200K	0.18%	43
2020 Q1	$986K	Sell	23,252 -1,168	-5%	-$60.3K	0.11%	53
2019 Q4	$1.49M	Hold	24,420	–	–	0.13%	47
2019 Q3	$1M	Sell	24,420 -2,692	-10%	-$129K	0.08%	55
2019 Q2	$1.28M	Sell	27,112 -3,204	-11%	-$128K	0.08%	59
2019 Q1	$1.08M	Sell	30,316 -4,081	-12%	-$141K	0.07%	64
2018 Q4	$983K	Sell	34,397 -22,603	-40%	-$786K	0.05%	78
2018 Q3	$2.53M	Hold	57,000	–	–	0.08%	75
2018 Q2	$3.35M	Buy	+57,000	New	+$3.25M	0.09%	71

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WS Management's CRSP Position: Q1 2024 in Review

WS Management sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 18,876 shares — an estimated $1.18M sold.

WS Management first reported a position in CRSP in Q2 2018 and held it in 23 quarters. The position peaked at $3.35M in Q2 2018. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

WS Management reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
WS Management sold 18,876 CRISPR Therapeutics shares in Q1 2024, an estimated $1.18M.
WS Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 23 quarters.
WS Management's CRISPR Therapeutics position peaked at $3.35M in Q2 2018.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on WS Management's 13F filing for Q1 2024, filed 14 May 2024.